Plain-English translation of NCT06682130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called glofitamab works well when combined with autologous stem cell transplant—a procedure where your own blood stem cells are collected, the cancer is treated intensively, and the cells are put back into your body. The study focuses on people with diffuse large B-cell lymphoma (a type of aggressive blood cancer) that has returned or stopped responding to previous treatments. Depending on how well the medication works for you initially, you may receive it before the transplant, during recovery, or as ongoing maintenance therapy.
Many patients with aggressive lymphoma that returns or resists standard chemotherapy need stronger treatments, but stem cell transplant alone doesn't always work. This trial is testing whether this new medication can improve the chances of success when used alongside transplant.
You likely qualify if…
You likely don't qualify if…
Your participation starts after you've received at least two prior treatments for your lymphoma. Based on how your cancer responds to your second-line treatment, you'll be placed into one of three groups that determine your next steps. Group A (partial response or positive blood tests) receives the new medication to help prepare for stem cell transplant. Group B (complete response and clear blood tests) proceeds directly to stem cell transplant. Group C (stable or worsening disease) receives two cycles of the medication first, then may proceed to transplant or continue medication based on results. After transplant, you'll receive follow-up medication and regular monitoring to track how well the treatment is working and your overall health.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China